Exscientia (NASDAQ:EXAI) Stock Price Down 2.8%

Exscientia plc (NASDAQ:EXAI)’s share price fell 2.8% during mid-day trading on Monday . The stock traded as low as $5.11 and last traded at $5.17. 192,023 shares changed hands during trading, a decline of 70% from the average session volume of 631,275 shares. The stock had previously closed at $5.32.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on EXAI shares. Morgan Stanley reiterated an “equal weight” rating and set a $7.00 price objective on shares of Exscientia in a research note on Monday, April 22nd. Barclays reiterated an “equal weight” rating and issued a $5.00 target price on shares of Exscientia in a research report on Tuesday, August 13th. Finally, TD Cowen reissued a “hold” rating on shares of Exscientia in a report on Friday, August 9th.

Exscientia Stock Down 1.1 %

The stock has a market cap of $635.87 million, a P/E ratio of -4.06 and a beta of 0.85. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.05. The stock’s 50-day moving average is $5.21 and its 200-day moving average is $5.39.

Exscientia (NASDAQ:EXAI) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). The firm had revenue of $5.60 million for the quarter. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. As a group, research analysts anticipate that Exscientia plc will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

A number of institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in Exscientia by 112.1% in the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after acquiring an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Exscientia by 76.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company’s stock valued at $53,000 after buying an additional 4,029 shares during the last quarter. Walled Lake Planning & Wealth Management LLC bought a new position in Exscientia in the 4th quarter worth approximately $64,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Exscientia during the second quarter worth approximately $54,000. Finally, New Republic Capital LLC bought a new stake in shares of Exscientia in the fourth quarter valued at approximately $128,000. 41.58% of the stock is currently owned by institutional investors and hedge funds.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.